Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 75.4% in September

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 10,500 shares, a decrease of 75.4% from the August 31st total of 42,600 shares. Based on an average daily trading volume, of 201,200 shares, the days-to-cover ratio is presently 0.1 days.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY traded down $0.04 during trading on Wednesday, reaching $11.95. The stock had a trading volume of 36,105 shares, compared to its average volume of 257,225. The stock has a market capitalization of $21.63 billion, a PE ratio of 171.29 and a beta of 0.38. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.90 and a quick ratio of 0.72. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $14.64. The business's 50-day moving average price is $11.75 and its 200 day moving average price is $10.64.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.24 earnings per share (EPS) for the quarter. The firm had revenue of $3.03 billion during the quarter. Astellas Pharma had a return on equity of 7.79% and a net margin of 1.17%. As a group, equities analysts predict that Astellas Pharma will post 0.54 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.